Nyxoah SA announced a Memorandum of Understanding with Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the United Arab Emirates and a subsidiary of PureHealth, the region’s largest healthcare group. The MoU positions SSMC as a regional center for Nyxoah’s Genio hypoglossal nerve stimulation therapy, creating a high‑volume implant program and a training hub for surgeons, sleep physicians and referring clinicians across the Middle East.
The agreement is not a binding commercial contract and does not disclose any financial commitments. It represents a strategic entry point for Nyxoah into a market with a large patient population and a high prevalence of obstructive sleep apnea (OSA). The partnership aligns with Nyxoah’s expansion narrative, which has seen the company grow from a European and U.S. focus to a global presence following FDA approval of Genio in August 2025.
Nyxoah’s CEO Olivier Taelman said, "Given the high prevalence of Obstructive Sleep Apnea in the Middle East, this initiative supports our vision to offer new treatment options…" The MoU will enable SSMC to train clinicians and surgeons, potentially accelerating early adoption of Genio in the region and leveraging PureHealth’s extensive network to reach patients who may benefit from the therapy.
Nyxoah’s financial position supports this expansion. In Q4 2025, the company reported net revenue of approximately €5.7 million and held €47.9 million in cash, cash equivalents and financial assets as of December 31, 2025. In December 2025, Nyxoah also secured a €22.5 million convertible bond tranche, providing additional capital for growth initiatives.
The partnership underscores Nyxoah’s commitment to expanding access to its lead product, Genio, and demonstrates the company’s confidence in the Middle East market as a key growth engine beyond its established European and U.S. operations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.